Does treating H. Pylori reduce the incidence of gastric cancer?
Randomised placebo-controlled trial.
At 7.5 years, incidence of gastric cancer was not significantly different between groups (treatment: 0.86%, n=7; placebo: 1.35%, n=11; p=0.33). In people without precancerous lesions at baseline, risk of gastric cancer was significantly lower for treatment compared with placebo (incidence of gastric cancer: treatment n=0; placebo n=6; p=0.02) but there was no difference among people with precancerous lesions (n=7 and 5, respectively). Smoking (hazard ratio [HR] 6.2, 95% CI 2.3 to 16.5) and older age (HR per 1 year 1.10, 95% CI 1.05 to 1.15) were independent predictors of gastric cancer risk.
Incidence of gastric cancer was similar between H. pylori eradication and placebo groups over 7.5 years of follow-up. However, it was significantly reduced in a subgroup of people without precancerous lesions at baseline.
Le texte complet de cet article est disponible en PDF.
Elsevier Ltd. Tous droits réservés.